Dallas, TX, January 30, 2018 --(PR.com
)-- Today JF2 Capital Partners (JF2), a Dallas, Texas venture capital firm, announced its growth capital investment in Pearland, Texas-based Adient Medical. Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications.
Founded in 2012, Adient Medical is leading the development of a totally absorbable vascular filter for the prevention of pulmonary embolism; the nation’s third largest killer claiming the lives of 100,000 to 300,000 Americans each year - more than breast cancer, AIDS, and traffic fatalities combined.
“Adient Medical is a company that impressed us with their game-changing medical device platform and we are pleased to announce our investment in this promising medical company,” said Jon Frankel, Founder of JF2. “The Adient team has done an incredible job, and we are excited about the company’s potential to save lives with this technology,” said Aaron Pierce, Managing Director of JF2. “Mitch Eggers, President and Chief Executive Officer of Adient, is very impressive and we look forward to what’s in store for Adient Medical.”
About JF2 Capital Partners
JF2 Capital Partners is a family office venture capital firm based in Dallas, Tx. Founded in 2017, JF2 Capital is interested in investing in early stage companies spanning a diverse array of industries. JF2 Capital works with dynamic management teams to build sustainable value in businesses leveraging extensive operational experience in growing and scaling organizations. With more than 20 years of proven success in starting, growing, and monetizing companies we have an extensive track record of accelerating growth in early stage companies. For more information, visit JF2Capital.com.